ADHD Therapeutics Market Size, Product Trends, Key Companies, Revenue Share Analysis Till 2027
| ADHD Therapeutics |
Attention deficit hyperactivity disorder (ADHD) is a neurodevelopmental disorder with a group of behavioral symptoms that include hyperactivity, inattentiveness and impulsiveness. The symptoms of ADHD begin in childhood and can continue through adolescence and adulthood. As per the report published by Market Research Future (MRFR), the global ADHD therapeutics market is registered to grow steadily till the end of 2024.
Market
Drivers and Restraints:
The symptoms of ADHD
such as lack of attention, hyperactivity and impulsivity hamper proper
functioning and development of an individual. Increasing awareness regarding
neurodevelopmental disorders and easy availability of diagnostic guidelines
over the internet is projected to boost the growth of the global ADHD
therapeutics market.
Changing lifestyles
and value systems along with the factors like genetic inheritance and premature
birth are resulting to the rise in prevalence of ADHD among children in the age
group of 4-17 years, which in turn is propelling the growth of the global ADHD
therapeutics market. Increasing availability of online platforms for therapists
that assure anonymity of the patient is inclining more individuals towards
undergoing therapeutic treatment for ADHD, which in turn is fueling the
expansion of the global ADHD therapeutics market
However,
underdiagnosis of ADHD due to the existence of comorbid conditions in children,
lack of awareness and low availability of non-stimulant drugs to treat ADHD in
various regions are likely to hamper the expansion of the global ADHD
therapeutics market during the forecast period.
Request Free
Sample Copy at: https://www.marketresearchfuture.com/sample_request/1573
Market
Segmentation:
The global ADHD
therapeutics market has been segmented on the basis of drug type and
distribution channel. Based on drug type, the ADHD therapeutics market is
segmented into stimulants and non-stimulants. The stimulants segment is
sub-segmented into amphetamine, methylphenidate, dextroamphetamine,
lisdexamfetamine and others. The non-stimulants segment is sub-segmented into
atomoxetine, bupropion, guanfacine and clonidine
Based on
distribution channel, the ADHD therapeutics market is segmented into hospitals,
clinics, pharmacies, research laboratories and others.
Regional
Analysis:
Geographically, the
global ADHD therapeutics market is segmented into four major regions such as
North America, Europe, Asia Pacific and the Middle East and Africa. The ADHD
therapeutics market in the North America region accounts for the dominant share
in the global ADHD therapeutics market owing to the increasing prevalence of
ADHD in the children and high healthcare expenditure by the population in this
region. The ADHD therapeutics market in the Europe region is projecting
significant growth owing to the increased research and development for the
introduction of more effective drugs in this region. The Asia Pacific region is
anticipated to grow at a notable pace in the coming years due to increased
awareness regarding ADHD and its available treatments. Whereas, the Middle East
and Africa region is projecting steady growth in the global ADHD market owing
to the low awareness and poor primary health care in the underdeveloped areas
of this region.
Industry
Updates:
In August 2018,
Ironshore Pharmaceuticals & Development, Inc., a subsidiary of Highland
Therapeutics Inc., has received FDA approval for the New Drug Application for
Jornay PM (methylphenidate) which was formerly known as HLD200 which is used
for the treatment of ADHD in patients of the age six and older
In August 2018, FDA
has issued a Complete Response Letter (CRL) to Sunovion Pharmaceutical asking
for further clinical data to evaluate the efficacy of dasotraline, the ADHD
drug.
Key Players:
The prominent
players profiled by MRFR in the report on the global ADHD therapeutics market
are Concordia International Corp., Eli Lilly and Company, Highland Therapeutics
Inc., Janssen Global Services LLC, NEOS Therapeutics Inc., Novartis AG, Noven
Pharmaceuticals Inc., Pfizer Inc., Shire, Teva Pharmaceutical and others.
Browse
Detailed TOC with COVID-19 Impact Analysis at:https://www.marketresearchfuture.com/reports/adhd-therapeutics-market-1573
About Market
Research Future:
At Market Research
Future (MRFR), we enable our customers to unravel the complexity of various
industries through our Cooked Research Report (CRR), Half-Cooked Research
Reports (HCRR), & Consulting Services. MRFR team have supreme objective to
provide the optimum quality market research and intelligence services to our
clients.
Contact us:
Market Research
Future (part of Wantstats Research and Media Private Limited),
99 Hudson Street,
5Th Floor,
New York, New York
10013
United States of
America
+1 628 258 0071
Email: sales@marketresearchfuture.com
Comments
Post a Comment